Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Lightens Message to Cody Laboratories

By Drug Discovery Trends Editor | April 13, 2009

CODY, Wyo. (AP) – Federal regulators are easing recently announced restrictions on the manufacture of a liquid drug produced by Cody Laboratories.

The labs and parent Lannett Co. of Philadelphia last week received US Food and Drug Administration orders to cease production of painkilling morphine sulfate in a dosage not federally approved. The agency was concerned about a 20-milligram-per-milliliter concentration of the drug used to ease pain in people who are dying.

Cody Laboratories and Lannett have since been informed they will be allowed to produce the dosage until an authorized revision or alternative therapy is available.

Lannett CEO Arthur Bedrosian had expressed confidence in the company’s products and said Lannett would work with FDA to resolve concerns.

FDA spokeswoman Rita Chappelle said the agency estimates that about two percent of all prescriptions written in the United States are for drugs not approved.

Critics of the FDA had questioned the need to crack down on a prescription drug used to relieve extreme pain in the dying, while over-the-counter products such as ‘miracle’ weight-loss pills appear largely unregulated.

‘We just took a separate action against nearly 80 dietary supplements,’ Chappelle said.

She said FDA enforcement is based on risk analysis.

‘If the product has had serious adverse events associated with it and public health could be at risk, those are the products we will prioritize,’ she said.

Chappelle said the FDA has been reaching out to manufacturers of unauthorized products and ‘trying to get them to come in and work through the process.’

She would not comment on the likely cost or timetable for obtaining FDA approval of any drug, but said that because other forms of liquid morphine have been approved in different dosages, action on the 20 milligram-per-milliliter dosage might follow an abbreviated process.

Release Date: April 11, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50